Compare TTMI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | RYTM |
|---|---|---|
| Founded | 1978 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.4B |
| IPO Year | 2000 | 2017 |
| Metric | TTMI | RYTM |
|---|---|---|
| Price | $64.01 | $111.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $73.25 | ★ $127.31 |
| AVG Volume (30 Days) | ★ 2.1M | 955.8K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.88 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $2,782,990,000.00 | $174,334,000.00 |
| Revenue This Year | $20.48 | $47.34 |
| Revenue Next Year | $9.21 | $57.18 |
| P/E Ratio | $48.81 | ★ N/A |
| Revenue Growth | 17.88 | ★ 54.92 |
| 52 Week Low | $15.78 | $45.91 |
| 52 Week High | $80.58 | $122.20 |
| Indicator | TTMI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 57.36 |
| Support Level | $61.38 | $109.99 |
| Resistance Level | $80.58 | $115.05 |
| Average True Range (ATR) | 4.34 | 5.19 |
| MACD | -1.38 | 0.77 |
| Stochastic Oscillator | 11.82 | 54.98 |
TTM Technologies Inc manufactures technology solutions, including mission systems, radio frequency (RF) components/RF microwave/microelectronic assemblies, quick-turn and technologically printed circuit boards (PCB). The company is based in the United States and derives roughly half of its revenue domestically. It organizes itself into two segments: printed circuit boards and RF&S Components. The printed circuit boards segment, which contributes the majority of revenue, offers a range of printed circuit boards as well as layout design and simulation, and testing services. TTM Technologies' products are used in manufacturing, networking, telecommunications, computing, aerospace, and medical fields.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.